Featured Publications

INOVIO is focused on rapidly bringing to market precisely designed DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

EClinicalMedicine
December 2020

Immunogenicity of a DNA vaccine candidate for COVID-19

Nature Communications
May 2020

Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine — Preliminary Report

The New England Journal of Medicine
October 2017

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

The Lancet Infectious Diseases
July 2019

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

The Lancet
September 2015

Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers

The Journal of Infectious Diseases
March 2019

Immuno-Oncology (Non HPV-Associated)

Title	Disease Target	Product
Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT Molecular Therapy — November 2017	hTERT	INO-5401
Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity Cancer Immunology Research — September 2013	hTERT	INO-5401
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity Molecular Therapy — February 2017	WT1	INO-5401
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens Molecular Therapy — March 2020	PSA	INO-5151
Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses Human Vaccines — January 2011	PSA, PSMA	INO-5401

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases